Perioperative Blood Transfusion as a Poor Prognostic Factor After Aggressive Surgical Resection for Hilar Cholangiocarcinoma

Journal of Gastrointestinal Surgery

Volumn 19, Issue 5, 2015, Pages 866-879

  Kimura, Norihisa ^a   Toyoki, Yoshikazu ^a   Ishido, Keinosuke ^a   Kudo, Daisuke ^a   Yakoshi, Yuta ^a   Tsutsumi, Shinji ^a   Miura, Takuya ^a   Wakiya, Taiichi ^a   Hakamada, Kenichi ^a  

^a HIROSAKI UNIVERSITY   (Japan)

Author keywords

Aggressive surgery; Blood transfusion; Hepatectomy; Hilar cholangiocarcinoma; Prognosis

Indexed keywords

ADULT; AGED; BILE DUCT NEOPLASMS; BLOOD TRANSFUSION; EPIDEMIOLOGY; FEMALE; HUMAN; INTRAHEPATIC BILE DUCT; JAPAN; KLATSKIN TUMOR; LIVER RESECTION; MALE; MIDDLE AGED; MORTALITY; PERIOPERATIVE PERIOD; PROCEDURES; PROGNOSIS; RETROSPECTIVE STUDY; RISK FACTOR; SURVIVAL RATE; TRENDS; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; BILE DUCT NEOPLASMS; BILE DUCTS, INTRAHEPATIC; BLOOD TRANSFUSION; FEMALE; HEPATECTOMY; HUMANS; JAPAN; KLATSKIN TUMOR; MALE; MIDDLE AGED; PERIOPERATIVE CARE; PROGNOSIS; RETROSPECTIVE STUDIES; RISK FACTORS; SURVIVAL RATE;

EID: 84939999347     PISSN: 1091255X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11605-014-2741-8     Document Type: Article

References (84)

1. Klempnauer J, Ridder GJ, Werner M, et al. What constitutes long-term survival after surgery for hilar cholangiocarcinoma? Cancer 1997; 79:26–34.
2. Launois B, Terblanche J, Lakehal M, et al. Proximal bile duct cancer: high resectability rate and 5-year survival. Ann Surg 1999; 230:266–275.
3. Rea DJ, Heimbach JK, Rosen CB, et al. Liver transplantation with neoadjuvant chemoradiation is more effective than resection for hilar cholangiocarcinoma. Ann Surg 2005;242:451–458.
4. Nimura Y, Hayakawa N, Kamiya J, et al. Hepatic segmentectomy with caudate lobe resection for bile duct carcinoma of the hepatic hilus. World J Surg 1990; 14:535–544.
5. Washburn WK, Lewis WD, Jenkins RL. Aggressive surgical resection for cholangiocarcinoma. Arch Surg 1995; 130:270–276.
6. Neuhaus P, Jonas S, Bechstein WO, et al. Extended resections for hilar cholangiocarcinoma. Ann Surg 1999; 230:808–819.
7. Jarnagin WR, Fong Y, DeMatteo RP, et al. Staging, resectability, and outcome in 225 patients with hilar cholangiocarcinoma. Ann Surg 2001; 234:507–519.
8. Kitagawa Y, Nagino M, Kamiya J, et al. Lymph node metastasis from hilar cholangiocarcinoma: audit of 110 patients who underwent regional and paraaortic node dissection. Ann Surg 2001; 233:385–392.
9. Nimura Y, Hayakawa N, Kamiya J, et al. Combined portal vein and liver resection for carcinoma of the biliary tract. Br J Surg 1991; 78:727–731.
10. Ebata T, Nagino M, Kamiya J, et al. Hepatectomy with portal vein resection for hilar cholangiocarcinoma: audit of 52 consecutive cases. Ann Surg 2003; 238:720–727.
11. Sakamoto Y, Sano T, Shimada K, et al. Clinical significance of reconstruction of the right hepatic artery for biliary malignancy. Langenbecks Arch Surg 2006; 391:203–208.
12. Nagino M, Nimura Y, Nishio H, et al. Hepatectomy with simultaneous resection of the portal vein and hepatic artery for advanced perihilar cholangiocarcinoma: an audit of 50 consecutive cases. Ann Surg 2010; 252:115–23.
13. Makuuchi M, Thai BL, Takayasu K, et al. Preoperative portal embolization to increase safety of major hepatectomy for hilar bile duct carcinoma: a preliminary report. Surgery 1990; 107:521–527.
14. Imamura H, Shimada R, Kubota M, et al. Preoperative portal vein embolization: an audit of 84 patients. Hepatology 1999; 29:1099–1105.
15. Abdalla EK, Barnett CC, Doherty D, et al. Extended hepatectomy in patients with hepatobiliary malignancies with and without preoperative portal vein embolization. Arch Surg 2002; 137:675–681.
16. Kawasaki S, Imamura H, Kobayashi A, et al. Results of surgical resection for patients with hilar bile duct cancer: application of extended hepatectomy after biliary drainage and hemihepatic portal vein embolization. Ann Surg 2003; 238:84–92.
17. Hemming AW, Reed AI, Fujita S, et al. Surgical management of hilar cholangiocarcinoma. Ann Surg 2005; 241:693–702.
18. Nagino M, Kamiya J, Nishio H, et al. Two hundred forty consecutive portal vein embolizations before extended hepatectomy for biliary cancer: surgical outcome and long-term follow-up. Ann Surg 2006; 243:364–372.
19. Kosuge T, Yamamoto J, Shimada K, et al. Improved surgical results for hilar cholangiocarcinoma with procedures including major hepatic resection. Ann Surg 1999; 230:663–671.
20. de Boer MT, Molenaar IQ, Porte RJ. Impact of blood loss on outcome after liver resection. Dig Surg 2007; 24:259–264.
21. Nagino M, Nimura Y, Kamiya J, et al. Changes in hepatic lobe volume in biliary tract cancer patients after right portal vein embolization. Hepatology 1995; 21:434–439.
22. Uesaka K, Nimura Y, Nagino M. Changes in hepatic lobar function after right portal vein embolization. An appraisal by biliary indocyanine green excretion. Ann Surg 1996; 223:77–83.
23. Nimura Y, Hayakawa N, Kamiya J, et al. Hepatopancreatoduodenectomy for advanced carcinoma of the biliary tract. Hepatogastroenterology 1991; 38:170–175.
24. Miyazaki M, Kato A, Ito H, et al. Combined vascular resection in operative resection for hilar cholangiocarcinoma: does it work or not? Surgery 2007; 141:581–588.
25. Gerhards MF, van Gulik TM, de Wit LT, et al. Evaluation of morbidity and mortality after resection for hilar cholangiocarcinoma—a single center experience. Surgery 2000; 127:395–404.
26. Shimizu H, Kimura F, Yoshidome H, et al. Aggressive surgical resection for hilar cholangiocarcinoma of the left-side predominance: radicality and safety of left-sided hepatectomy. Ann Surg 2010; 251:281–286.
27. International Union Against Cancer (UICC). TNM classification of malignant tumours. 7th ed. Hoboken, NJ: Wiley-Blackwell, 2009.
28. Albores-Saavedra J, Henson D, Klimstra D. Tumors of the gallbladder, extrahepatic bile ducts, and ampulla of Vater. 3rd ed. Washington, DC: Armed Forces Institute of Pathology, 2000.
29. Wakai T, Shirai Y, Moroda T, et al. Impact of ductal resection margin status on long-term survival in patients undergoing resection for extrahepatic cholangiocarcinoma. Cancer 2005; 103:1210–1216.
30. Sasaki R, Takeda Y, Funato O, et al. Significance of ductal margin status in patients undergoing surgical resection for extrahepatic cholangiocarcinoma. World J Surg 2007; 31:1788–1796.
31. Endo I, House MG, Klimstra DS, et al. Clinical significance of intraoperative bile duct margin assessment for hilar cholangiocarcinoma. Ann Surg Oncol 2008; 15:2104–2112.
32. Ojima H, Kanai Y, Iwasaki M, et al. Intraductal carcinoma component as a favorable prognostic factor in biliary tract carcinoma. Cancer Sci 2009; 100:62–70.
33. Nakanishi Y, Kondo S, Zen Y, et al. Impact of residual in situ carcinoma on postoperative survival in 125 patients with extrahepatic bile duct carcinoma. J Hepatobiliary Pancreat Sci 2010; 17:166–173.
34. Igami T, Nagino M, Oda K, et al. Clinicopathologic study of cholangiocarcinoma with superficial spread. Ann Surg 2009; 249:296–302.
35. Mullen JT, Ribero D, Reddy SK, et al. Hepatic insufficiency and mortality in 1,059 noncirrhotic patients undergoing major hepatectomy. J Am Coll Surg 2007; 204:854–864.
36. Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg 2004; 240:205–213.
37. Ito F, Cho CS, Rikkers LF, Weber SM. Hilar cholangiocarcinoma: current management. Ann Surg 2009; 250:210–218.
38. Seyama Y, Kubota K, Sano K, et al. Long-term outcome of extended hemihepatectomy for hilar bile duct cancer with no mortality and high survival rate. Ann Surg 2003; 238:73–83.
39. Jarnagin WR, Bowne W, Klimstra DS, et al. Papillary phenotype confers improved survival after resection of hilar cholangiocarcinoma. Ann Surg 2005; 241:703–714.
40. Hasegawa S, Ikai I, Fujii H, et al. Surgical resection of hilar cholangiocarcinoma: analysis of survival and postoperative complications. World J Surg 2007; 31:1256–1263.
41. Klempnauer J, Ridder GJ, von Wasielewski R, et al. Resectional surgery of hilar cholangiocarcinoma: a multivariate analysis of prognostic factors. J Clin Oncol 1997; 15:947–954.
42. Miyazaki M, Ito H, Nakagawa K, et al. Aggressive surgical approaches to hilar cholangiocarcinoma: hepatic or local resection? Surgery 1998; 123:131–136.
43. Su CH, Tsay SH, Wu CC, et al. Factors influencing postoperative morbidity, mortality, and survival after resection for hilar cholangiocarcinoma. Ann Surg 1996; 223:384–394.
44. Todoroki T, Kawamoto T, Koike N, et al. Radical resection of hilar bile duct carcinoma and predictors of survival. Br J Surg 2000; 87:306–313.
45. Tsao JI, Nimura Y, Kamiya J, et al. Management of hilar cholangiocarcinoma: comparison of an American and a Japanese experience. Ann Surg 2000; 232:166–174.
46. Igami T, Nishio H, Ebata T, et al. Surgical treatment of hilar cholangiocarcinoma in the “new era”: the Nagoya University experience. J Hepatobiliary Pancreat Sci 2010; 17:449–454.
47. Ito F, Agni R, Rettammel RJ, et al. Resection of hilar cholangiocarcinoma: concomitant liver resection decreases hepatic recurrence. Ann Surg 2008; 248:273–279.
48. Opelz G, Terasaki PI. Absence of immunization effect in human-kidney retransplantation. N Engl J Med 1978; 299:369–374.
49. Peters WR, Fry RD, Fleshman JW, Kodner IJ. Multiple blood transfusions reduce the recurrence rate of Crohn's disease. Dis Colon Rectum 1989; 32:749–753.
50. Burrows L, Tartter P. Effect of blood transfusions on colonic malignancy recurrent rate. Lancet 1982; 2(8299):662–662.
51. Voogt PJ, van de Velde CJ, Brand A, et al. Perioperative blood transfusion and cancer prognosis. Different effects of blood transfusion on prognosis of colon and breast cancer patients. Cancer 1987; 59:836–843.
52. Blumberg N, Agarwal MM, Chuang C. Relation between recurrence of cancer of the colon and blood transfusion. Br Med J (Clin Res Ed) 1985; 290:1037–1039.
53. Foster RS, Jr., Costanza MC, Foster JC, et al. Adverse relationship between blood transfusions and survival after colectomy for colon cancer. Cancer 1985; 55:1195–1201.
54. Parrott NR, Lennard TW, Taylor RM, et al. Effect of perioperative blood transfusion on recurrence of colorectal cancer. Br J Surg 1986; 73:970–973.
55. Tartter PI. The association of perioperative blood transfusion with colorectal cancer recurrence. Ann Surg 1992; 216:633–638.
56. Heiss MM, Mempel W, Delanoff C, et al. Blood transfusion-modulated tumor recurrence: first results of a randomized study of autologous versus allogeneic blood transfusion in colorectal cancer surgery. J Clin Oncol 1994; 12:1859–1867.
57. Busch OR, Hop WC, Marquet RL, Jeekel J. The effect of blood transfusions on survival after surgery for colorectal cancer. Eur J Cancer 1995; 31A:1226–1228.
58. Kaneda M, Horimi T, Ninomiya M, et al. Adverse affect of blood transfusions on survival of patients with gastric cancer. Transfusion 1987; 27:375–377.
59. Fong Y, Karpeh M, Mayer K, Brennan MF. Association of perioperative transfusions with poor outcome in resection of gastric adenocarcinoma. Am J Surg 1994; 167:256–260.
60. Hyung WJ, Noh SH, Shin DW, et al. Adverse effects of perioperative transfusion on patients with stage III and IV gastric cancer. Ann Surg Oncol 2002; 9:5–12.
61. Cameron JL, Crist DW, Sitzmann JV, et al. Factors influencing survival after pancreaticoduodenectomy for pancreatic cancer. Am J Surg 1991; 161:120–125.
62. Millikan KW, Deziel DJ, Silverstein JC, et al. Prognostic factors associated with resectable adenocarcinoma of the head of the pancreas. Am Surg 1999; 65:618–624.
63. Yeh JJ, Gonen M, Tomlinson JS, et al. Effect of blood transfusion on outcome after pancreaticoduodenectomy for exocrine tumour of the pancreas. Br J Surg 2007; 94:466–472.
64. Ueda M, Endo I, Nakashima M, et al. Prognostic factors after resection of pancreatic cancer. World J Surg 2009; 33:104–110.
65. Kneuertz PJ, Patel SH, Chu CK, et al. Effects of perioperative red blood cell transfusion on disease recurrence and survival after pancreaticoduodenectomy for ductal adenocarcinoma. Ann Surg Oncol 2011; 18:1327–1334.
66. Gozzetti G, Mazziotti A, Grazi GL, et al. Liver resection without blood transfusion. Br J Surg 1995; 82:1105–1110.
67. Asahara T, Katayama K, Itamoto T, et al. Perioperative blood transfusion as a prognostic indicator in patients with hepatocellular carcinoma. World J Surg 1999; 23:676–680.
68. Yamamoto J, Kosuge T, Takayama T, et al. Perioperative blood transfusion promotes recurrence of hepatocellular carcinoma after hepatectomy. Surgery 1994; 115:303–309.
69. Poon RT, Fan ST, Lo CM, et al. Improving survival results after resection of hepatocellular carcinoma: a prospective study of 377 patients over 10 years. Ann Surg 2001; 234:63–70.
70. Shiba H, Ishida Y, Wakiyama S, et al. Negative impact of blood transfusion on recurrence and prognosis of hepatocellular carcinoma after hepatic resection. J Gastrointest Surg 2009; 13:1636–1642.
71. Wang CC, Iyer SG, Low JK, et al. Perioperative factors affecting long-term outcomes of 473 consecutive patients undergoing hepatectomy for hepatocellular carcinoma. Ann Surg Oncol 2009; 16:1832–1842.
72. Stephenson KR, Steinberg SM, Hughes KS, et al. Perioperative blood transfusions are associated with decreased time to recurrence and decreased survival after resection of colorectal liver metastases. Ann Surg 1988; 208:679–687.
73. Kooby DA, Stockman J, Ben-Porat L, et al. Influence of transfusions on perioperative and long-term outcome in patients following hepatic resection for colorectal metastases. Ann Surg 2003; 237:860–870.
74. Poon RT, Fan ST, Lo CM, et al. Improving perioperative outcome expands the role of hepatectomy in management of benign and malignant hepatobiliary diseases: analysis of 1222 consecutive patients from a prospective database. Ann Surg 2004; 240:698–710.
75. Gomez D, Morris-Stiff G, Wyatt J, et al. Surgical technique and systemic inflammation influences long-term disease-free survival following hepatic resection for colorectal metastasis. J Surg Oncol 2008; 98:371–376.
76. Nagino M, Kamiya J, Arai T, et al. One hundred consecutive hepatobiliary resections for biliary hilar malignancy: preoperative blood donation, blood loss, transfusion, and outcome. Surgery 2005; 137:148–155.
77. Regimbeau JM, Fuks D, Le Treut YP, et al. Surgery for hilar cholangiocarcinoma: a multi-institutional update on practice and outcome by the AFC-HC study group. J Gastrointest Surg 2011; 15:480–488.
78. Nuzzo G, Giuliante F, Ardito F, et al. Improvement in perioperative and long-term outcome after surgical treatment of hilar cholangiocarcinoma: results of an Italian multicenter analysis of 440 patients. Arch Surg 2012; 147:26–34.
79. Liu CL, Fan ST, Lo CM, et al. Improved operative and survival outcomes of surgical treatment for hilar cholangiocarcinoma. Br J Surg 2006; 93:1488–1494.
80. Young AL, Igami T, Senda Y, et al. Evolution of the surgical management of perihilar cholangiocarcinoma in a Western centre demonstrates improved survival with endoscopic biliary drainage and reduced use of blood transfusion. HPB (Oxford) 2011; 13:483–493.
81. Gascon P, Zoumbos NC, Young NS. Immunologic abnormalities in patients receiving multiple blood transfusions. Ann Intern Med 1984; 100:173–177.
82. Kaplan J, Sarnaik S, Gitlin J, Lusher J. Diminished helper/suppressor lymphocyte ratios and natural killer activity in recipients of repeated blood transfusions. Blood 1984; 64:308–310.
83. Upile T, Jerjes W, Mahil J, et al. An explanation for the worsened prognosis in some cancer patients of perioperative transfusion: the time-dependent release of biologically active growth factors from stored blood products. Eur Arch Otorhinolaryngol 2011; 268:1789–1794.
84. Goeppert B, Frauenschuh L, Zucknick M, et al. Prognostic impact of tumour-infiltrating immune cells on biliary tract cancer. Br J Cancer 2013; 109:2665–2674